Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer

Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Fernandes, Maria Gabriela O., Sousa, Catarina, Jacob, Maria, Almeida, Leonor, Santos, Vanessa, Araújo, David, Novais Bastos, Hélder, Magalhães, Adriana, Cirnes, Luís, Moura, Conceição Souto, Queiroga, Henrique, Cruz-Martins, Natália, Hespanhol, Venceslau
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8136429/
https://ncbi.nlm.nih.gov/pubmed/34026599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.602924
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados